Doxazosin Mesylate Tablet
NDC 59762-1391
Product Information
Doxazosin Mesylate is a NDA AUTHORIZED GENERIC-approved product labeled by Mylan Pharmaceuticals Inc.. Doxazosin is used alone or with other drugs to treat high blood pressure (hypertension). It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 59762-1391 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
WHITE (C48325 - OBLONG)
OVAL (C48345)
DIAMOND (C48338)
CAPSULE (C48336)
9 MM
12 MM
CN1;VLE
CN;2;VLE
CN;4;VLE
CN;8;VLE
2
Code Structure Chart
Product Details
What is NDC 59762-1391?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DOXAZOSIN MESYLATE (UNII: 86P6PQK0MU)
- DOXAZOSIN (UNII: NW1291F1W8) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- LACTOSE, UNSPECIFIED FORM (UNII: J2B2A4N98G)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 197625 - doxazosin mesylate 1 MG Oral Tablet
- RxCUI: 197625 - doxazosin 1 MG Oral Tablet
- RxCUI: 197625 - doxazosin (as doxazosin mesylate) 1 MG Oral Tablet
- RxCUI: 197626 - doxazosin mesylate 2 MG Oral Tablet
- RxCUI: 197626 - doxazosin 2 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.